Marinus Pharmaceuticals reports Q3 EPS (42c), consensus (41c)
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 12 2024
0mins
Should l Buy ?
Q3 Financial Performance: Sangamo reported Q3 revenue of $8.5 million, falling short of the consensus estimate of $9.4 million, while highlighting significant advancements in their regulatory pathway for ST-920 in Fabry disease.
Pipeline Developments: The company is progressing with its neurology pipeline, having submitted its first IND application for ST-503 aimed at treating intractable pain, and is actively seeking additional funding to enhance its programs and technologies.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
